Satellite maker Terran Orbital sees annual revenue climb near $100 million

Satellite maker Terran Orbital sees annual revenue climb near 0 million


Terran Orbital, a specialist in manufacturing small satellites, reported fourth-quarter results on Tuesday, with annual revenue nearing $100 million as it continued to build its order backlog.

For the full year of 2022, Terran Orbital brought in $94.2 million in revenue – more than double its 2021 total.

related investing news

We're adding to this oil stock after it fell 6% since last week

CNBC Investing Club

The Irvine, California-based company reported that revenue grew to $31.9 million in the fourth quarter, up from $27.8 million in the third quarter. Terran Orbital’s adjusted EBITDA loss doubled, however, both on a quarter-over-quarter and year-over-year basis, to $26.1 million, which the company attributed to an increase in expenses such as payroll, sales and marketing.

Shares of Terran Orbital slipped about 8% Tuesday from the stock’s previous close at $1.73.

Sign up here to receive weekly editions of CNBC’s Investing in Space newsletter.

While Terran Orbital’s order backlog fell on a quarter-over-quarter basis, to $170.8 million in Q4 from $198 million in Q3, that number does not include its $2.4 billion deal with Rivada, announced in February. Terran Orbital’s year-end backlog was for about 60 satellites, with the Rivada contract adding around 300 to that total.

Terran Orbital delivered 19 satellites during the fourth quarter, including 10 under a contract through the Pentagon’s Space Development Agency. The company is expanding its manufacturing facilities to be able to make up to 250 satellites a year.



Source

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi
Business

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

Signage outside Johnson & Johnson offices in Irvine, California, US, on Friday, Oct. 10, 2025. Kyle Grillot | Bloomberg | Getty Images Johnson & Johnson on Wednesday said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to rival best-selling shots. The FDA approved the pill, Icotyde, to treat […]

Read More
Macy’s store revamp shows progress, but company expects sales to fall this year
Business

Macy’s store revamp shows progress, but company expects sales to fall this year

Macy’s on Wednesday beat Wall Street’s quarterly sales and profit expectations as its namesake brand showed signs of progress, yet still gave a cautious outlook for the year ahead. For the fiscal year, the company – which includes its namesake chain, higher-end department store Bloomingdale’s and beauty retailer Bluemercury – said it expects sales of […]

Read More
Disney embarks on new chapter as Josh D’Amaro takes over as CEO
Business

Disney embarks on new chapter as Josh D’Amaro takes over as CEO

Larissa Manoela and Josh D’Amaro, Chairperson of Walt Disney Parks and Resorts, wave to the audience after Panel Disney Experiences during Day 2 of the D23 Brazil: A Disney Experience at Transamerica Expo Center on November 09, 2024 in Sao Paulo, Brazil. Ricardo Moreira | Getty Images Disney is turning the page on a new […]

Read More